T. Rowe Price Associates
HGEN

T. Rowe Price Associates’s HUMANIGEN, INC. HGEN Stock Holding History

T. Rowe Price Associates’s Portfolio HGEN Stock Details HGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,069
Closed -$37K – 3036
2021
Q4 		$37K Sell
10,069
-552
-5% -$3.23K ﹤0.01% 2941
2021
Q3 		$63K Sell
10,621
-100
-0.9% -$1.41K ﹤0.01% 2895
2021
Q2 		$186K Buy
+10,721
New +$195K ﹤0.01% 2746

Other funds holding HGEN

VCM
Valiant Capital Management San Francisco, California $1.74B AUM 64.05% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates's HGEN Position: Q1 2022 in Review

T. Rowe Price Associates sold out of HUMANIGEN, INC. (HGEN) in Q1 2022, closing a stake of 10,069 shares — an estimated $37K sold.

T. Rowe Price Associates first reported a position in HGEN in Q2 2021 and held it in 3 quarters. The position peaked at $186K in Q2 2021. 83 funds tracked by Wall St. Rank hold HGEN as of Q1 2022.

  • T. Rowe Price Associates reported no remaining HUMANIGEN, INC. position as of Q1 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 10,069 HUMANIGEN, INC. shares in Q1 2022, an estimated $37K.
  • T. Rowe Price Associates first reported a position in HUMANIGEN, INC. in Q2 2021 and held it in 3 quarters.
  • T. Rowe Price Associates's HUMANIGEN, INC. position peaked at $186K in Q2 2021.
  • 83 funds tracked by Wall St. Rank held HUMANIGEN, INC. as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.